153 related articles for article (PubMed ID: 7522428)
1. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors.
Byrnes VW; Emini EA; Schleif WA; Condra JH; Schneider CL; Long WJ; Wolfgang JA; Graham DJ; Gotlib L; Schlabach AJ
Antimicrob Agents Chemother; 1994 Jun; 38(6):1404-7. PubMed ID: 7522428
[TBL] [Abstract][Full Text] [Related]
2. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
3. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
Larder BA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2664-9. PubMed ID: 1282792
[TBL] [Abstract][Full Text] [Related]
4. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
[TBL] [Abstract][Full Text] [Related]
5. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Larder BA; Kellam P; Kemp SD
Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
[TBL] [Abstract][Full Text] [Related]
6. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.
Lacey SF; Larder BA
J Virol; 1994 May; 68(5):3421-4. PubMed ID: 7512165
[TBL] [Abstract][Full Text] [Related]
7. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
Borkow G; Arion D; Wainberg MA; Parniak MA
Antimicrob Agents Chemother; 1999 Feb; 43(2):259-63. PubMed ID: 9925515
[TBL] [Abstract][Full Text] [Related]
8. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
9. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
10. Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.
Arion D; Sluis-Cremer N; Parniak MA
J Biol Chem; 2000 Mar; 275(13):9251-5. PubMed ID: 10734063
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
[TBL] [Abstract][Full Text] [Related]
12. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
Kim EY; Vrang L; Oberg B; Merigan TC
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
[TBL] [Abstract][Full Text] [Related]
14. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
[TBL] [Abstract][Full Text] [Related]
15. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus.
Yang SS; Pattabiraman N; Gussio R; Pallansch L; Buckheit RW; Bader JP
Leukemia; 1997 Apr; 11 Suppl 3():89-92. PubMed ID: 9209308
[TBL] [Abstract][Full Text] [Related]
17. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
18. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
19. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Vrang L; Walbers J; Zhang H; Oberg B; Vandamme AM; Camarasa MJ; De Clercq E
Virology; 1993 Jan; 192(1):246-53. PubMed ID: 7685964
[TBL] [Abstract][Full Text] [Related]
20. Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.
Imamichi T; Berg SC; Imamichi H; Lopez JC; Metcalf JA; Falloon J; Lane HC
J Virol; 2000 Dec; 74(23):10958-64. PubMed ID: 11069990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
